prostate cancer

2 curated biomarkers

← Back to browse

FDA-approved treatments

BRCA1
- Lynparza (olaparib) [fda]
- Talzenna (talazoparib) [fda]
BRCA2
- Lynparza (olaparib) [fda]
- Talzenna (talazoparib) [fda]

Prevalence

BRCA1
Pathogenic germline BRCA1 variants are found in approximately 5% of unselected breast cancers and up to 15% of ovarian cancers.[fda]
BRCA2
Pathogenic germline BRCA2 variants are found in approximately 5% of unselected breast cancers and are also associated with elevated risk of ovarian, pancreatic, and prostate cancer.[fda]

Tests / detection method

BRCA1
germline genetic testing, somatic NGS
BRCA2
germline genetic testing, somatic NGS

Therapeutic pipeline

BRCA1
- Next-generation PARP1-selective inhibitors [fda]
BRCA2
- Next-generation PARP1-selective inhibitors [fda]

PubMed Central · Oct 1, 2026
Impact of PI-RADS During Active Surveillance for Prostate Cancer on Pathological Findings at Repeat Biopsy.
Read at PubMed Central
PubMed Central · Sep 3, 2026
Sociodemographic trends in prostate cancer: insights from the All of Us Research Program.
Read at PubMed Central
PubMed Central · Sep 2, 2026
Imaging Modality and Outcomes of Metastasis-Directed Therapy in Oligometastatic Castration-Resistant Prostate Cancer: An Updated Analysis of the PRECISE-MDT Cohort.
Read at PubMed Central
PubMed Central · Sep 2, 2026
Integrative Surface Antigen Profiling of KLK2 and STEAP1 in Advanced Prostate Cancer.
Read at PubMed Central
PubMed Central · Sep 2, 2026
Amanitin-Based Fc-Small Molecule-Drug Conjugates with Noncleavable Linker: A Novel Therapeutic Strategy for Prostate Cancer Targeted Therapy.
Read at PubMed Central
American Cancer Society · Sep 1, 2026
Prostate Cancer Awareness Month: American Cancer Society Reports New Cases Are Up 3% but Earlier Diagnosis Improves Patient Outcomes
Read at American Cancer Society
PubMed Central · Sep 1, 2026
Phase Ib Trial of Bavdegalutamide (ARV-110) in Combination with Abiraterone for Metastatic Prostate Cancer.
Read at PubMed Central
PubMed Central · Sep 1, 2026
The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial.
- BRCA1 (biomarker)
- BRCA2 (biomarker)
Read at PubMed Central
PubMed Central · Sep 1, 2026
Survival and Mortality Predictors in Prostate Cancer: A Retrospective Cohort of 10 556 Brazilian Patients.
Read at PubMed Central
PubMed Central · Sep 1, 2026
Advancing Prostate Cancer Survivorship through Transatlantic Consortium Science: The iCCaRE Initiative.
Read at PubMed Central
PubMed Central · Sep 1, 2026
Distinct Prognostic Roles of Grade Group and Intraductal Carcinoma of the Prostate in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors.
Read at PubMed Central
PubMed Central · Sep 1, 2026
Annona crassiflora seed extract modulates histological and molecular markers associated with prostate cancer progression in TRAMP mice.
Read at PubMed Central
PubMed Central · Sep 1, 2026
Real-World Outcomes of Olaparib in Japanese Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer: Exploratory Analysis of BRCA2 Loss and Microsatellite Instability Status.
- BRCA2 (biomarker)
Read at PubMed Central
PubMed Central · Sep 1, 2026
Dynamic Predictions and Predictimands for Salvage Therapy in Recurrent Prostate Cancer Using Joint Models.
Read at PubMed Central
PubMed Central · Sep 1, 2026
Dietary Fat Intake and Mortality Among Patients With Nonmetastatic Prostate Cancer.
Read at PubMed Central
PubMed Central · Sep 1, 2026
High-definition spatial transcriptomics visualizes the cellular and molecular architecture underlying perineural invasion in localized prostate cancer.
Read at PubMed Central
PubMed Central · Sep 1, 2026
Comparative Prognostic Impact of Two-Dimensional and Three-Dimensional Computed Tomography-Based Sarcopenia Indices in Metastatic Castration-Sensitive Prostate Cancer.
Read at PubMed Central
PubMed Central · Sep 1, 2026
SLC3A1 Mitigates Ferroptosis and Promotes Enzalutamide Resistance in Prostate Cancer.
Read at PubMed Central
PubMed Central · Aug 29, 2026
Prognostic value of circulating tumor DNA and copy-number alterations in patients receiving tandem [(225)Ac]Ac-/[(177)Lu]Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer: a prospective observational study.
Read at PubMed Central
PubMed Central · Aug 29, 2026
Expected costs and benefits of genetic counselling and germline genetic testing in metastatic prostate cancer.
Read at PubMed Central

prostate cancer

FDA-approved treatments

Prevalence

Tests / detection method

Therapeutic pipeline

Recent news for prostate cancer

Impact of PI-RADS During Active Surveillance for Prostate Cancer on Pathological Findings at Repeat Biopsy.

Sociodemographic trends in prostate cancer: insights from the All of Us Research Program.

Imaging Modality and Outcomes of Metastasis-Directed Therapy in Oligometastatic Castration-Resistant Prostate Cancer: An Updated Analysis of the PRECISE-MDT Cohort.

Integrative Surface Antigen Profiling of KLK2 and STEAP1 in Advanced Prostate Cancer.

Amanitin-Based Fc-Small Molecule-Drug Conjugates with Noncleavable Linker: A Novel Therapeutic Strategy for Prostate Cancer Targeted Therapy.

Prostate Cancer Awareness Month: American Cancer Society Reports New Cases Are Up 3% but Earlier Diagnosis Improves Patient Outcomes

Phase Ib Trial of Bavdegalutamide (ARV-110) in Combination with Abiraterone for Metastatic Prostate Cancer.

The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial.

Survival and Mortality Predictors in Prostate Cancer: A Retrospective Cohort of 10 556 Brazilian Patients.

Advancing Prostate Cancer Survivorship through Transatlantic Consortium Science: The iCCaRE Initiative.

Distinct Prognostic Roles of Grade Group and Intraductal Carcinoma of the Prostate in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors.

Annona crassiflora seed extract modulates histological and molecular markers associated with prostate cancer progression in TRAMP mice.

Real-World Outcomes of Olaparib in Japanese Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer: Exploratory Analysis of BRCA2 Loss and Microsatellite Instability Status.

Dynamic Predictions and Predictimands for Salvage Therapy in Recurrent Prostate Cancer Using Joint Models.

Dietary Fat Intake and Mortality Among Patients With Nonmetastatic Prostate Cancer.

High-definition spatial transcriptomics visualizes the cellular and molecular architecture underlying perineural invasion in localized prostate cancer.

Comparative Prognostic Impact of Two-Dimensional and Three-Dimensional Computed Tomography-Based Sarcopenia Indices in Metastatic Castration-Sensitive Prostate Cancer.

SLC3A1 Mitigates Ferroptosis and Promotes Enzalutamide Resistance in Prostate Cancer.

Prognostic value of circulating tumor DNA and copy-number alterations in patients receiving tandem [(225)Ac]Ac-/[(177)Lu]Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer: a prospective observational study.

Expected costs and benefits of genetic counselling and germline genetic testing in metastatic prostate cancer.